Crocs (NASDAQ:CROX) Updates FY 2026 Earnings Guidance

Posted by Stanley Muller on Aug 1st, 2026

Crocs (NASDAQ:CROX – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 13.700-14.000 for the period, compared to the consensus earnings per share estimate of 13.670. The company issued revenue guidance of $4.1 billion-$4.1 billion, compared to the consensus revenue estimate of $4.1 billion. Crocs also updated its Q3 2026 guidance to 3.200-3.300 EPS.

Crocs Trading Up 3.5%

Shares of Crocs stock opened at $128.01 on Friday. Crocs has a 12-month low of $73.21 and a 12-month high of $140.42. The firm’s 50 day simple moving average is $125.85 and its two-hundred day simple moving average is $103.36. The company has a current ratio of 1.49, a quick ratio of 1.04 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $6.36 billion, a price-to-earnings ratio of 11.06, a PEG ratio of 1.28 and a beta of 1.55.

Crocs (NASDAQ:CROX – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The textile maker reported $4.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.20. Crocs had a net margin of 14.64% and a return on equity of 47.75%. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the firm posted ($8.82) earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Crocs has set its FY 2026 guidance at 13.700-14.000 EPS and its Q3 2026 guidance at 3.200-3.300 EPS. Analysts predict that Crocs will post 13.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CROX shares. Wall Street Zen raised shares of Crocs from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Robert W. Baird set a $163.00 target price on shares of Crocs in a research report on Friday. Monness Crespi & Hardt upped their price objective on shares of Crocs from $130.00 to $160.00 and gave the company a “buy” rating in a research note on Friday. Needham & Company LLC boosted their price objective on Crocs from $132.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Finally, Barclays raised their target price on Crocs from $110.00 to $118.00 and gave the stock an “equal weight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Crocs has an average rating of “Hold” and an average price target of $135.09.

View Our Latest Report on CROX

Insider Transactions at Crocs

In other news, CEO Andrew Rees sold 32,688 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $118.09, for a total transaction of $3,860,125.92. Following the sale, the chief executive officer owned 743,293 shares of the company’s stock, valued at approximately $87,775,470.37. This represents a 4.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company’s stock.

Key Headlines Impacting Crocs

Here are the key news stories impacting Crocs this week:

Positive Sentiment: Second-quarter results exceeded expectations. Crocs reported adjusted earnings of $4.55 per share versus the $4.35 consensus estimate, while revenue reached a record $1.18 billion, above expectations of approximately $1.15 billion and up 2.6% year over year. The Crocs Brand surpassed $1 billion in quarterly revenue for the first time. Crocs Second-Quarter Results
Positive Sentiment: Full-year 2026 guidance was raised. Crocs increased adjusted EPS guidance to $13.70-$14.00, above the prior consensus estimate of $13.67, while maintaining revenue expectations of roughly $4.1 billion. Management also authorized an additional $1.5 billion for share repurchases, leaving approximately $2 billion available for buybacks. Crocs Q2 Earnings Beat
Positive Sentiment: Analysts remain constructive. Monness Crespi & Hardt raised its price target from $130 to $160 and assigned a Buy rating. Bank of America also reaffirmed its Buy rating and $160 target, citing brand momentum and potential margin upside. Bank of America Crocs Rating
Neutral Sentiment: Growth was uneven across the portfolio. Direct-to-consumer and international demand helped results, but HEYDUDE revenue declined 5.7% to $179 million, highlighting continued challenges outside the core Crocs Brand.
Negative Sentiment: Third-quarter guidance disappointed investors. Crocs projected adjusted EPS of $3.20-$3.30 and revenue of about $996 million, below Wall Street expectations of roughly $3.53-$3.55 in EPS and $1 billion in revenue. Tariff pressure and HEYDUDE weakness are expected to weigh on near-term profitability, overshadowing the quarterly beat and causing an initial selloff. Crocs Third-Quarter Guidance

Institutional Trading of Crocs

Several institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC increased its position in Crocs by 399.0% in the 3rd quarter. AQR Capital Management LLC now owns 1,266,799 shares of the textile maker’s stock valued at $105,841,000 after acquiring an additional 1,012,943 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in Crocs by 78.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 907,988 shares of the textile maker’s stock valued at $77,651,000 after purchasing an additional 399,964 shares during the last quarter. Incision Capital Management LP acquired a new position in Crocs during the fourth quarter worth about $27,794,000. Patient Capital Management LLC lifted its stake in Crocs by 28.9% in the 4th quarter. Patient Capital Management LLC now owns 758,797 shares of the textile maker’s stock valued at $64,892,000 after buying an additional 170,003 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Crocs by 1,171.9% in the 3rd quarter. Two Sigma Investments LP now owns 162,040 shares of the textile maker’s stock valued at $13,538,000 after purchasing an additional 149,300 shares during the last quarter. Hedge funds and other institutional investors own 93.44% of the company’s stock.

About Crocs

(Get Free Report)

Crocs, Inc is a global footwear designer, developer and distributor best known for its lightweight, proprietary Croslite™ foam-clog construction. The company’s product portfolio encompasses a range of styles, including clogs, sandals, slides, boots and sneakers, all featuring the slip-resistant, odor-resistant and cushion-providing qualities of the Croslite material. Crocs distributes its products through an omnichannel network that includes e-commerce platforms, company-owned retail stores, authorized dealers and wholesale partners.

Founded in 2002 by Scott Seamans, Lyndon “Duke” Hanson and George Boedecker Jr., Crocs launched its first clog on the island of Vail, Colorado.

Earnings History and Estimates for Crocs (NASDAQ:CROX)

Receive News & Ratings for Crocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crocs and related companies with MarketBeat.com's FREE daily email newsletter.